Мычка В. Б., Кириллова М. Ю., Кузнецова И. В., Войченко Н. А., Федорович А. А., Балахонова Т. В., Прохорова Ю. В., Вышиванюк В. А. Современная комбинированная гормональная терапия у женщин в ранней постменопаузе. Кардиоваскулярная терапия и профилактика. 2012;11(4):42-51.
1. Mosca L, Benjamin EJ, Berra K, et al. A Guideline from the American Heart Association. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women–2011 Update. Circulation 2011; 123: 1243–62.
2. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012; 15(2): 105–14.
3. Suhih GT, Adamyan LV. The condition and the aspects of reproductive health in Russian population. Contemporarytechnologies in diagnostics and treatment of gynecological disorders. M.: Pantori 2007; p. 5–19 Russian (Сухих Г.Т., Адамян Л.В. Состояние и перспективы репродуктивного здоровья населения России. Современные технологии в диагностике и лечении гинекологических заболеваний. Под ред. В.И. Кулакова, Л.В. Адамян. М.: Пантори 2007; 5–19).
4. Rosano GМ, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl 1): 19–27.
5. Boggia J, Thijs L, Hansen TW, et al. Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. Hypertension 2011; 57(3): 397–405.
6. Gast G-C M, Pop V JM, Samsioe GN, et al. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause 2011; 18(2): 146–51.
7. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, et al. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118: 1234–40.
8. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308(5728): 1583–77.
9. Karas R, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI timing is everything. Menopausal Medicine 2003;10: 8–12.
10. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001; 41(6): 875–86. 11. Hodges GJ, Sharp L, Clements RE et al. Influence of age, sex, and aerobic capacity on forearm and skin blood flow and vascular conductance. Eur J Appl Physiol 2010; 109: 1009–15.
11. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease the Framingham study. Ann Intern Med 1976; 85: 447–52.
12. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Preven Rehabil 2011; 18 (6): 775–89.
13. Kvernmo HD, Stefanovska A, Bracic A, et al. Oscillations in the human cutaneous blood perfusion signal modified by endothelium-dependent and endothelium-independent vasodilators. Microvasc Res 1999; 57: 298–309.
14. Jonson JM, Kellog DL. Local thermal control of the human cutaneous circulation. J Appl Physiol 2010; 109: 1229–38.
15. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 16(6): 716–27.
16. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48(2): 243–53.
17. Preston R, White W, Pitt B, et al. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804.
18. Preston RA, Norris PM, Alonso AB, et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14: 408–41.
19. Elger W, Beier S., Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68(10–13): 891–905.
20. Saranyaratana W, Sakondhavat C, Silaruks S, et al. Effect of hormone therapy on lipid profile in menopausal women. J Med Assoc Thai 2006; 89 Suppl 4: S37–41.
21. Sudhir K, Esler MD, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 1997; 30: 1538–43.
22. Pinto S, Virdis A, Ghiadoni L, et al. Endogenous estrogen and acetylcholineinduced vasodilatation in normotensive women. Hypertension 1997; 29: 268–73.
23. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91.
24. Brooks-Asplund EM, Kenney WL. Chronic hormone replacement therapy does not alter resting or maximal skin blood flow. J Appl Physiol 1998; 85: 505-10.
25. Arildsson M, Asker CL, Salerud EG, Strömberg T. Skin capillary appearance and skin microvascular perfusion due to topical application of analgesia cream. Microvasc Res 2000; 59: 14–23.
26. Vuilleumitr P, Decosterd D, Maillard M, et al. Postischemic forearm skin reactive hyperemia is related to cardiovascular risk factors in a healthy female population. J Hypertension 2002; 20: 1753–7.
27. Kuznetsova IV, Mychka VB, Voichenko NA, et al. Cardiovascular diseases prevention in postmenopausal women. Menopause Selected papers of the 13th World Congress on Menopause Rome, June 8–11, 2011: 352–4.
28. Mychka VB, Kuznetsova IV, Yureneva SV, et al. Hormonal Replacing Therapy in Women with Menopausal Symptoms and Evaluation of the Effects on Cardiovascular System.«Gynecological Endocrinology 2012» Vol. XXXIV №1 2012; 257–9.
29. Tolstov SN, Salov IA, Mychka VB, et al. The main approaches in managing premenopause women. Russian journal of Cardiology 2011; 6: 98–104. Russian (Толстов С.Н., Салов И.А., Мычка В.Б. и др. Основные принципы ведения женщин в пременопаузе. Российский кардиологический журнал 2011; 6: 98–104).
